Flag of the European Union EU Clinical Trials Register Help

Clinical trials for breast cancer

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44381   clinical trials with a EudraCT protocol, of which   7393   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
    Select Country:
    		 Select Age Range:
    Select Trial Status:
    		 Select Trial Phase:
    Select Gender:
    Select Date Range:
    to
    Select Rare Disease:
    IMP with orphan designation in the indication
    Orphan Designation Number:
    Results Status:
    Clear advanced search filters
     
    5 result(s) found for: breast cancer. Displaying page 1 of 1.
    EudraCT Number: 2012-005788-28 Sponsor Protocol Number: ICG1 Start Date*: 2014-01-24
    Sponsor Name:Landeskrankenhaus Fedkirch
    Full Title: Influence of Body Mass Index on the identification rate of indocyanine green (ICG) fluorescence mapping for sentinel lymph node detection in early breast cancer
    Medical condition: A feasibility study of indocyanine green (ICG) fluorescence mapping for sentinel lymph node detection in early breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-001664-22 Sponsor Protocol Number: 2011-001664-22 Start Date*: 2011-12-22
    Sponsor Name:Medizinische Universität Wien - Universitätsklinik für Frauenheilkunde
    Full Title: A prospective, randomized, multicenter study to evaluate the impact of Darbepoetin alfa in combination with Ferric(III)-Carboxymaltose in comparison to Darbepoetin alfa and Ferric(III)-Carboxymalto...
    Medical condition: This is a prospective, multicenter, randomized, comparative, parallel group, phase IV study to assess the efficacy and safety of FCM 800mg or Darbepoetin alfa 500µg or the combination of FCM 800mg ...
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2005-002643-89 Sponsor Protocol Number: PALO-05-02 Start Date*: 2005-12-14
    Sponsor Name:Helsinn Healthcare SA
    Full Title: Double-blind Study to Compare the Efficacy of Palonosetron with or without the use of Dexamethasone on Days 2 and 3, in the Prevention of Nausea and Vomiting Induced by Moderately Emetogenic Chemot...
    Medical condition: This is a non-inferiority study in chemotherapy-naïve female patients with breast cancer, age 18 years or older, who are scheduled to receive Moderately Emetogenic Chemotherapy (MEC).
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed) ES (Completed) AT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-003612-45 Sponsor Protocol Number: A9001502 Start Date*: 2019-09-06
    Sponsor Name:Pfizer Inc.
    Full Title: TREATMENT RESISTANCE FOLLOWING ANTI-CANCER THERAPIES (TRANSLATE)
    Medical condition: Cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-002080-93 Sponsor Protocol Number: EGF103659 Start Date*: 2006-10-06
    Sponsor Name:Glaxo SmithKline Research and Development Limited
    Full Title: An Open-Label Expanded Access Study of Lapatinib and Capecitabine Therapy in Subjects with ErbB2 Overexpressing Locally Advanced or Metastatic Breast Cancer
    Medical condition: ErbB2 Overexpressing Locally Advanced or Metastatic Breast Cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) NL (Completed) BE (Completed) PT (Completed) CZ (Completed) SK (Completed) IS (Completed) DE (Completed) AT (Completed) EE (Completed) GR (Completed) DK (Completed) FI (Completed) SE (Completed) IT (Prematurely Ended) MT (Completed) SI (Completed) GB (Completed) BG (Completed) ES (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Feb 14 20:17:19 CET 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA